This is a prospective, single-center, open-label pilot study of 68GA-PSMA-11 given at a
single time prior to PET/CT imaging in men with localized high risk prostate cancer or
biochemical recurrence. The imaging agent (68 Ga-PSMA 11 will be administered on an
outpatient basis. It will be administered prior to the PET/CT imaging. The objective is to
evaluate the distribution of 68GA-PSMA-11 in tissues and to determine if this alters the
planned clinical management.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System